Literature DB >> 11724859

Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.

Y Ike1, Y Arakawa, X Ma, K Tatewaki, M Nagasawa, H Tomita, K Tanimoto, S Fujimoto.   

Abstract

A total of 6,625 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates obtained from 278 hospitals throughout Japan were obtained between November and December 1997 and were examined for their sensitivities to vancomycin using Mueller Hinton (MH), brain heart infusion (BHI), agar plates, or the broth microdilution method. A concentrated inoculum of an MRSA strain or the use of highly enriched medium, such as BHI medium, allows an individual cell to grow on agar plates containing a vancomycin concentration greater than the MIC for the parent strain. However, cells of the colonies which grew on BHI agar plates containing the higher vancomycin concentrations did not acquire a level of vancomycin resistance greater than that of the parent strain and were not subpopulations of heterogeneously vancomycin-resistant MRSA. There was no significance in the fact that these colonies grew on the higher concentration of vancomycin: none showed stable resistance to vancomycin at a concentration above the MIC for the parent strain, and no cell from these colonies showed a relationship between the MIC and the ability of these colonies to grow on higher concentrations of vancomycin. The vancomycin MIC was not above 2 microg/ml for any of the cells originating from these colonies. No Mu3-type heterogeneously resistant MRSA strains, which constitutively produce subpopulations from MRSA clinical isolates with intermediate vancomycin resistance at a high frequency, were detected. There was a unipolar distribution of the MICs ranging from 0.25 to 2 microg of vancomycin/ml among the 6,625 MRSA clinical isolates, indicating that there was no Mu50-type intermediately vancomycin-resistant MRSA (MIC, 8 microg/ml by National Committee for Clinical Laboratory Standards criteria) among the clinical isolates, and there was no evidence of dissemination of Mu3-type MRSA heteroresistant to vancomycin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724859      PMCID: PMC88563          DOI: 10.1128/JCM.39.12.4445-4451.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Isolation of Pre-Adaptive Mutants in Bacteria by Sib Selection.

Authors:  L L Cavalli-Sforza; J Lederberg
Journal:  Genetics       Date:  1956-05       Impact factor: 4.562

2.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

3.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

4.  Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

Authors:  J Ariza; M Pujol; J Cabo; C Peña; N Fernández; J Liñares; J Ayats; F Gudiol
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

5.  Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-01-07       Impact factor: 17.586

6.  Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.

Authors:  H Hanaki; K Kuwahara-Arai; S Boyle-Vavra; R S Daum; H Labischinski; K Hiramatsu
Journal:  J Antimicrob Chemother       Date:  1998-08       Impact factor: 5.790

7.  Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

Authors:  L Cui; H Murakami; K Kuwahara-Arai; H Hanaki; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

8.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

9.  Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals.

Authors:  S K Hubert; J M Mohammed; S K Fridkin; R P Gaynes; J E McGowan; F C Tenover
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

10.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.

Authors:  T L Smith; M L Pearson; K R Wilcox; C Cruz; M V Lancaster; B Robinson-Dunn; F C Tenover; M J Zervos; J D Band; E White; W R Jarvis
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

View more
  12 in total

1.  Antimicrobial resistance and epidemiological typing of methicillin-resistant Staphylococcus aureus in Ireland (North and South), 1999.

Authors:  A S Rossney; P McDonald; H Humphreys; G M Glynn; C T Keane
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-16       Impact factor: 3.267

Review 2.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 3.  Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.

Authors:  B P Howden; P B Ward; P D R Johnson; P G P Charles; M L Grayson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

4.  First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia.

Authors:  S Al-Obeid; Q Haddad; A Cherkaoui; J Schrenzel; P François
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

5.  Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.

Authors:  Sandra S Richter; Sarah W Satola; Emily K Crispell; Kristopher P Heilmann; Cassie L Dohrn; Fathollah Riahi; Andrew J Costello; Daniel J Diekema; Gary V Doern
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

6.  Usefulness of PCR-restriction fragment length polymorphism typing of the coagulase gene to discriminate arbekacin-resistant methicillin-resistant Staphylococcus aureus strains.

Authors:  Keiko Ishino; Naofumi Tsuchizaki; Jun Ishikawa; Kunimoto Hotta
Journal:  J Clin Microbiol       Date:  2006-12-13       Impact factor: 5.948

Review 7.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  Nationwide surveillance for Staphylococcus aureus with reduced susceptibility to vancomycin in Korea.

Authors:  Hong Bin Kim; Wan Beom Park; Ki Deok Lee; Young Joo Choi; Sang Won Park; Myoung-Don Oh; Eui-Chong Kim; Kang Won Choe
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

9.  Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital.

Authors:  Yasar Nakipoglu; Sengul Derbentli; Atahan A Cagatay; Handan Katranci
Journal:  BMC Infect Dis       Date:  2005-05-05       Impact factor: 3.090

Review 10.  Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.

Authors:  Shanshan Zhang; Xiaoxi Sun; Wenjiao Chang; Yuanyuan Dai; Xiaoling Ma
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.